Genetic and pharmacologic evidence implicating the p85 alpha, but not p85 beta, regulatory subunit of PI3K and Rac2 GTPase in regulating oncogenic KIT-induced transformation in acute myeloid leukemia and systemic mastocytosis.

Genetic and pharmacologic evidence implicating the p85 alpha, but not p85 beta, regulatory subunit of PI3K and Rac2 GTPase in regulating oncogenic KIT-induced transformation in acute myeloid leukemia and systemic mastocytosis.

Item
http://www.wikidata.org/entity/Q42193246
Structural Basis for c-KIT Inhibition by the Suppressor of Cytokine Signaling 6 (SOCS6) Ubiquitin LigaseRational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AML.Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment.SHP2 is a target of the immunosuppressant tautomycetin.KIT signaling regulates MITF expression through miRNAs in normal and malignant mast cell proliferationGenetic disruption of the scaffolding protein, Kinase Suppressor of Ras 1 (KSR1), differentially regulates GM-CSF-stimulated hyperproliferation in hematopoietic progenitors expressing activating PTPN11 mutants D61Y and E76KRole of intracellular tyrosines in activating KIT-induced myeloproliferative diseaseRho kinase regulates the survival and transformation of cells bearing oncogenic forms of KIT, FLT3, and BCR-ABL.p85β regulatory subunit of class IA PI3 kinase negatively regulates mast cell growth, maturation, and leukemogenesis.Role of SHP2 phosphatase in KIT-induced transformation: identification of SHP2 as a druggable target in diseases involving oncogenic KIT.The multiple roles of phosphoinositide 3-kinase in mast cell biology.The protein tyrosine phosphatase, Shp2, positively contributes to FLT3-ITD-induced hematopoietic progenitor hyperproliferation and malignant disease in vivo.The emerging role of the phosphatidylinositol 3-kinase/ akt/mammalian target of rapamycin signaling network in cancer stem cell biology.Targeting protein tyrosine phosphatase SHP2 for therapeutic intervention.SHIP deficiency causes Crohn's disease-like ileitis.A novel interaction between fibroblast growth factor receptor 3 and the p85 subunit of phosphoinositide 3-kinase: activation-dependent regulation of ERK by p85 in multiple myeloma cells.Loss of epigenetic regulator TET2 and oncogenic KIT regulate myeloid cell transformation via PI3K pathway.
P2860

Genetic and pharmacologic evidence implicating the p85 alpha, but not p85 beta, regulatory subunit of PI3K and Rac2 GTPase in regulating oncogenic KIT-induced transformation in acute myeloid leukemia and systemic mastocytosis.

Item
http://www.wikidata.org/entity/Q42193246
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Genetic and pharmacologic evid ...... mia and systemic mastocytosis.
@en
Genetic and pharmacologic evid ...... mia and systemic mastocytosis.
@nl
type
label
Genetic and pharmacologic evid ...... mia and systemic mastocytosis.
@en
Genetic and pharmacologic evid ...... mia and systemic mastocytosis.
@nl
prefLabel
Genetic and pharmacologic evid ...... mia and systemic mastocytosis.
@en
Genetic and pharmacologic evid ...... mia and systemic mastocytosis.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P5875
P698
P932
P356
P1433
P1476
Genetic and pharmacologic evid ...... mia and systemic mastocytosis.
@en
P2093
P2860
P304
P31
P356
10.1182/BLOOD-2006-10-053058
P407
P433
P478
P577
P5875
P698
P932